Anatomy of the female pelvis is superbly delineated by MRI due to excellent soft tissue contrast. In patients with infertility, MRI is the best technique to evaluate suspected myomata. Since tumors are directly visualized, MRI can be an effective technique for staging cervical, uterine, and vaginal malignancies.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prevalence of non-vaccine high-risk HPV cervical infections in vaccinated women: a systematic review and meta-analysis.
BMC Infect Dis
January 2025
Programa de Pós-graduação em Ciências Farmacêuticas, Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil.
Background: Human Papillomavirus (HPV) is the most common sexually transmitted lower genital tract infection worldwide and the main etiological factor of cervical cancer (CC). Since 2006, vaccines have been implemented to reduce CC-related morbidity and mortality. This systematic review and meta-analysis aimed to evaluate the prevalence of cervical infections by non-vaccine high-risk HPV (HR-HPV) types in women vaccinated against types 16 and 18.
View Article and Find Full Text PDFSPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway.
Cell Death Discov
January 2025
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China.
PARPis resistance is a challenge in the treatment of ovarian cancer. To investigate the potential mechanism involved in olaparib resistance of ovarian cancer, high-throughput sequencing was performed on olaparib-resistant SKOV3 cell line named SK/Ola. SPHK1 was upregulated in SK/Ola cells and was related to the PFS and OS in ovarian cancer patients.
View Article and Find Full Text PDFUterine preservation in pyomyoma complicating uterine artery embolisation.
BMJ Case Rep
January 2025
Department of Radiology, All India Institute of Medical Science Bhopal, Bhopal, Madhya Pradesh, India.
Pyomyoma, a rare complication of uterine artery embolisation (UAE) for symptomatic fibroids, can closely mimic post-embolisation syndrome (PES), which typically presents with pain, fever and leucocytosis within the first week. Differentiating PES from pyomyoma is critical, as pyomyoma carries a higher risk of severe complications. We report a case of an unmarried nulliparous woman who developed pyomyoma following UAE for fibroids.
View Article and Find Full Text PDFNon-bacterial thrombotic endocarditis in a patient with high-grade serous ovarian carcinoma: diagnostic challenges and management insights.
BMJ Case Rep
January 2025
Cardiology, East Cheshire NHS Trust, Macclesfield, UK.
Non-bacterial thrombotic endocarditis (NBTE) is characterised by sterile vegetations on heart valves and often emerges in hypercoagulable states like malignancy. It is frequently underdiagnosed and only comes to light during postmortem examination. Early diagnosis and treatment with anticoagulation can help lower mortality.
View Article and Find Full Text PDFIntraperitoneal chemotherapy is now back for ovarian cancer.
Int J Clin Oncol
January 2025
Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
The Intraperitoneal Carboplatin for Ovarian Cancer (iPocc) trial demonstrated that intraperitoneal (IP) administration of carboplatin is more effective than intravenous (IV) administration for advanced ovarian cancer, especially in cases with large residual tumors, challenging previous assumptions that IP chemotherapy is only beneficial for small residual tumors. Additionally, the iPocc trial showed that IP chemotherapy has a comparable safety profile to IV chemotherapy, with the exception of port-related toxicities. This review summarizes the principles, development, and significance of IP chemotherapy and discusses its future potential in light of recent studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!